StockData
Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc. (RLMD) stock

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.01−0.60 (-16.62%)

Close on Nov 17, 2026Market cap $321.08MP/E –Yield –

Relmada Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for Relmada Therapeutics

Relmada Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Relmada Therapeutics figures

See a number that looks wrong?